Abstract: The present invention relates to a crystal form IV of organic acid salts of a compound represented by chemical formula 1, a preparation method thereof, and a pharmaceutical composition comprising same. The crystal form IV of organic acid salts of the compound represented by chemical formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile and/or a TGA profile.
| # | Name | Date |
|---|---|---|
| 1 | 202317074267-STATEMENT OF UNDERTAKING (FORM 3) [31-10-2023(online)].pdf | 2023-10-31 |
| 2 | 202317074267-REQUEST FOR EXAMINATION (FORM-18) [31-10-2023(online)].pdf | 2023-10-31 |
| 3 | 202317074267-PROOF OF RIGHT [31-10-2023(online)].pdf | 2023-10-31 |
| 4 | 202317074267-POWER OF AUTHORITY [31-10-2023(online)].pdf | 2023-10-31 |
| 5 | 202317074267-FORM 18 [31-10-2023(online)].pdf | 2023-10-31 |
| 6 | 202317074267-FORM 1 [31-10-2023(online)].pdf | 2023-10-31 |
| 7 | 202317074267-DRAWINGS [31-10-2023(online)].pdf | 2023-10-31 |
| 8 | 202317074267-DECLARATION OF INVENTORSHIP (FORM 5) [31-10-2023(online)].pdf | 2023-10-31 |
| 9 | 202317074267-COMPLETE SPECIFICATION [31-10-2023(online)].pdf | 2023-10-31 |
| 10 | 202317074267-MARKED COPIES OF AMENDEMENTS [16-04-2024(online)].pdf | 2024-04-16 |
| 11 | 202317074267-FORM 13 [16-04-2024(online)].pdf | 2024-04-16 |
| 12 | 202317074267-AMMENDED DOCUMENTS [16-04-2024(online)].pdf | 2024-04-16 |
| 13 | 202317074267-FORM 3 [29-04-2024(online)].pdf | 2024-04-29 |